Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Royalty Pharma

Tracked across 4 events · 32 articles · First seen Jul 07, 2026 · Last active Sep 05, 2026

Sentiment
28
Attention
4
Events
4
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
3 20
Business
Impact: Royalty Pharma acquires a royalty interest in cliramitug, expanding its development-stage pipeline with a potential blockbuster drug.
Jul 22, 2026 · 7 articles
4 0
Business
Impact: Royalty Pharma announced the trial failure and expects to recoup its investment due to protective structuring, reiterating its 2030 target.
Sep 04, 2026 · 12 articles
3 30
Business
Impact: Royalty Pharma provides up to $500 million in R&D funding for TEV-408, sharing in potential future royalties.
Jul 07, 2026 · 7 articles
4 60
Tech
Impact: Royalty Pharma has a strategic funding agreement with Teva for TEV '408, and positive results may increase the potential value of its investment.
Sep 02, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Royalty Pharma live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.